Mutations in the UL97 gene of cytomegalovirus (Herpesvirales: Herpesviridae: Cytomegalovirus: Human betaherpesvirus 5) associated with ganciclovir resistance in recipients of allogeneic hematopoietic stem cells
- Authors: Demin M.V.1, Tikhomirov D.S.1, Biderman B.V.1, Drokov M.Y.1, Sudarikov A.B.1, Tupoleva T.A.1, Filatov F.P.2,3
-
Affiliations:
- FSBI «National Medical Research Center for Hematology» of the Ministry of Health of Russia
- FSBRI «I.I. Mechnikov Research Institute of Vaccines and Sera»
- FSBI «National Research Centre for Epidemiology and Microbiology named after honorary academician N.F. Gamaleya» of the Ministry of Health of Russia
- Issue: Vol 67, No 1 (2022)
- Pages: 37-47
- Section: ORIGINAL RESEARCH
- URL: https://journals.rcsi.science/0507-4088/article/view/118192
- DOI: https://doi.org/10.36233/0507-4088-90
- ID: 118192
Cite item
Full Text
Abstract
Introduction. Infection caused by cytomegalovirus (CMV) is a serious problem for patients with weakened immunity, including patients with hematopoietic depression. The cases of complications associated with cytomegalovirus require antiviral therapy. However, during the natural mutation process, especially with prolonged use of drugs in suboptimal doses, CMV strains resistant to the action of antiviral drugs (such as ganciclovir, valganciclovir) may occur. Hypothetically, the emergence of resistance in the virus may cause a more aggressive course of infection, the ineffectiveness of antiviral therapy and, as a result, an increase in the number of deaths. In this regard, timely detection of mutations that can potentially lead to the resistance of the virus to antiviral drugs during hematopoietic stem cell transplantation (HSCT), as well as during organ and tissue transplantation, may be important when making a therapeutic decision. We describe three clinical cases for which the dynamics of the appearance of a mutant strain of CMV by the UL97 gene, which correlates with the viral load and clinical picture, is analyzed.
The aim of the study was to determine the timing of the occurrence of mutations in CMV phosphotransferase UL97 gene associated with resistance to antiviral drugs in patients with hemoblastoses after allogeneic hematopoietic stem cell (allo-HSCs) transplantation.
Material and methods. The study included 48 samples of CMV DNA isolated from the peripheral blood of three allo-HSCs recipients with CMV infection who were treated in the clinics of the FSBI «National Medical Research Center for Hematology» of the Ministry of Health of Russia with oncohematological diseases during 2015–2017. Patients received conditional codes (PR, PD, and FS). Mutations associated with antiviral therapy (AVT) resistance were identified in all patients. Sanger sequencing was used for mutation detection. The obtained DNA sequences were analyzed using Nucleotide BLAST and Genome compiler software. Mutations were searched in MRA mutation resistance analyzer software. The nucleotide sequences were compared with the UL97 reference sequence of the Merlin CMV strain using this software environment.
Results and discussion. For all patients in whom the virus strains containing C592G (PR), C607F (PD) and C603W (FS) mutations were detected, the timing of the mutation occurrence was determined at days 187, 124 and 1184, respectively. The emergence of mutations with a high resistance factor was shown to be accompanied by an increase in viral load (VL), the appearance of a clinical picture characteristic of CMV infection and a lack of an adequate response to therapy with ganciclovir and its derivatives.
Conclusion. Using these results, it is proposed to develop the test system based on random polymerase chain reaction (rPCR) to detect mutations in the most frequently encountered codons: M460I/V, C592G, A591V, A594T/V, L595F/S, C603W. Given that the data on the prevalence of these mutations were obtained from foreign sources, it is advisable to conduct similar studies on the frequency of mutations in the UL97 gene among the population of the Russian Federation in order to improve the quality and accuracy of test systems.
Full Text
##article.viewOnOriginalSite##About the authors
M. V. Demin
FSBI «National Medical Research Center for Hematology» of the Ministry of Health of Russia
Author for correspondence.
Email: memindisha@gmail.com
ORCID iD: 0000-0002-7579-3442
Mikhail V. Demin, Biologist, Researcher of the Virological Safety Laboratory
125167, Moscow
Russian FederationD. S. Tikhomirov
FSBI «National Medical Research Center for Hematology» of the Ministry of Health of Russia
Email: fake@neicon.ru
ORCID iD: 0000-0002-2553-6579
125167, Moscow
Russian FederationB. V. Biderman
FSBI «National Medical Research Center for Hematology» of the Ministry of Health of Russia
Email: fake@neicon.ru
ORCID iD: 0000-0002-6253-3334
125167, Moscow
Russian FederationM. Yu. Drokov
FSBI «National Medical Research Center for Hematology» of the Ministry of Health of Russia
Email: fake@neicon.ru
ORCID iD: 0000-0001-9431-8316
125167, Moscow
Russian FederationA. B. Sudarikov
FSBI «National Medical Research Center for Hematology» of the Ministry of Health of Russia
Email: fake@neicon.ru
ORCID iD: 0000-0001-9463-9187
125167, Moscow
Russian FederationT. A. Tupoleva
FSBI «National Medical Research Center for Hematology» of the Ministry of Health of Russia
Email: fake@neicon.ru
ORCID iD: 0000-0003-4668-9379
125167, Moscow
Russian FederationF. P. Filatov
FSBRI «I.I. Mechnikov Research Institute of Vaccines and Sera»; FSBI «National Research Centre for Epidemiology and Microbiology named after honorary academician N.F. Gamaleya» of the Ministry of Health of Russia
Email: fake@neicon.ru
ORCID iD: 0000-0002-2385-9251
105064, Moscow; 123098, Moscow
Russian FederationReferences
- Gerna G., Zavattoni M., Baldanti F., Furione M., Chezzi L., Revello M.G., et al. Circulating cFytomegalic endothelial cells are associated with high human cytomegalovirus (HCMV) load in AIDS patients with late-stage disseminated HCMV disease. J. Med. Virol. 1998; 55(1): 64–74.
- Göhring K., Hamprecht K., Jahn G. Antiviral drug- and multidrug resistance in cytomegalovirus infected SCT patients. Comput. Struct. Biotechnol. J. 2015; 13: 153–9. https://doi.org/10.1016/j.csbj.2015.01.003
- Piret J., Boivin G. Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance. Antiviral Res. 2019; 163: 91–105. https://doi.org/10.1016/j.antiviral.2019.01.011
- Schaeffer H.J., Beauchamp L., de Miranda P., Elion G.B., Bauer D.J., Collins P. 9-(2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group. Nature. 1978; 272(5654): 583–5. https://doi.org/10.1038/272583a0
- Chou S. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Rev. Med. Virol. 2008; 18(4): 233–46. https://doi.org/10.1002/rmv.574
- Göhring K., Wolf D., Bethge W., Mikeler E., Faul C., Vogel W., et al. Dynamics of coexisting HCMV-UL97 and UL54 drug-resistance associated mutations in patients after haematopoietic cell transplantation. J. Clin. Virol. 2013; 57(1): 43–9. https://doi.org/10.1016/j.jcv.2013.01.003
- Britt W. Cytomegalovirus. In: Remington J.S., ed. Infectious Diseases of the Fetus and Newborn Infant. Elsevier; 2011: 706–55.
- Komatsu T.E., Pikis A., Naeger L.K., Harrington P.R. Resistance of human cytomegalovirus to ganciclovir/valganciclovir: A comprehensive review of putative resistance pathways. Antiviral Res. 2014; 101: 12–25. https://doi.org/10.1016/j.antiviral.2013.10.011
- Biron K.K. Antiviral drugs for cytomegalovirus diseases. Antiviral Res. 2006; 71(2–3): 154–63. https://doi.org/10.1016/j.antiviral.2006.05.002
- Fischer L., Imrich E., Sampaio K.L., Hofmann J., Jahn G., Hamprecht K., et al. Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance. Antiviral Res. 2016; 131: 1–8. https://doi.org/10.1016/j.antiviral.2016.04.002
- Volfova P., Lengerova M., Lochmanova J., Dvorakova D., Ricna D., Palackova M., et al. Detecting human cytomegalovirus drug resistant mutations and monitoring the emergence of resistant strains using real-time PCR. J. Clin. Virol. 2014; 61(2): 270–4. https://doi.org/10.1016/j.jcv.2014.07.008
- Eckle T., Jahn G., Hamprecht K. The influence of mixed HCMV UL97 wildtype and mutant strains on ganciclovir susceptibility in a cell associated plaque reduction assay. J. Clin. Virol. 2004; 30(1): 50–6. https://doi.org/10.1016/j.jcv.2003.08.010
- Göhring K., Feuchtinger T., Mikeler E., Lang P., Jahn G., Handgretinger R., et al. Dynamics of the emergence of a human cytomegalovirus UL97 mutant strain conferring ganciclovir resistance in a pediatric stem-cell transplant recipient. J. Mol. Diagnostics. 2009; 11(4): 364–8. https://doi.org/10.2353/jmoldx.2009.080153
- Demin M.V., Biderman B.V., Glinshchikova O.A., Sudarikov A.B., Filatov F.P., Tikhomirov D.S., et al. Mutations in the cytomegalovirus UL97 gene associated with ganciclovir resistance in recipients of allogeneic hematopoietic stem cell transplants. Clin. Microbiol. Antimicrob. Chemother. 2019; 21(4): 352–7. https://doi.org/10.36488/cmac.2019.4.352-357
- Chou S., Waldemer R.H., Senters A.E., Michels K.S., Kemble G.W., Miner R.C., et al. Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. J. Infect. Dis. 2002; 185(2): 162–9. https://doi.org/10.1086/338362
Supplementary files
